Recent Advances in the Treatment of Advanced HER2+ Breast Cancer: SABCS 2024 - Episode 9

Insights From DESTINY-Breast12 Evaluating T-DXd in HER2+ Breast Cancer and Active and Stable Brain Metastases

, , , ,

Panelists discuss how the DESTINY-Breast12 trial evaluated trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer (mBC) with brain metastases, demonstrating encouraging intracranial responses and overall survival outcomes while maintaining a manageable safety profile consistent with previous T-DXd studies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Precision Medicine in Breast Cancer: Evolving Paradigms in HER2 Testing and Clinical Implications
    EP. 2: ADCs in HER2-Low Breast Cancer: Insights From DESTINY-Breast04, TROPiCS-02, and TROPION-Breast02
    EP. 3: T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights
    EP. 4: Emerging Data and Treatment Considerations in HER2 Ultralow Breast Cancer
    EP. 5: Patient-Reported Outcomes and Quality of Life Data With T-DXd in HER2-(Ultra) Low mBC
    EP. 6: Proactive AE Management and Prophylactic Strategies With TADCs in Breast Cancer
    EP. 7: Evolving Paradigms in HER2+ Advanced Breast Cancer With Brain Metastases
    EP. 8: Precision in CNS Targeting: Optimizing Management of Brain Metastases in HER2+ Breast Cancer
    Now Viewing
    EP. 9: Insights From DESTINY-Breast12 Evaluating T-DXd in HER2+ Breast Cancer and Active and Stable Brain Metastases
    EP. 10: Novel and Emerging Strategies for HER2+ Breast Cancer With Brain Metastases
    EP. 11: Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer
    EP. 12: SABCS Highlights and Future Directions in the Treatment of Breast Cancer

    Video content above is prompted by the following:

    Please review the recent findings from the DESTINY-Breast12 trial, highlighting study design, rationale, and key efficacy and safety data in patients with HER2+ mBC and brain metastases.

    x